1
项与 CD5/CD7 CAR-T(Essen Biotech) 相关的临床试验This is an Open, Single-arm, Clinical Study to Evaluate the Efficacy and Safety of Anti-CD7/CD5 CAR-T Cells in the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL), ETP-ALL, and Lymphoblastic Lymphoma (TLBL).
Chimeric antigen receptor (CAR)-modified T cells targeted against CD19 have demonstrated unprecedented successes in treating patients with hematopoietic and lymphoid malignancies. Besides CD19, many other molecules such as CD22, CD30,BCMA,CD123, etc. may be the potential to develop the corresponding CAR-T cells to treat patients whose tumors express those markers. In this study, investigators will evaluate the safety and efficacy of Sequential CAR-T Cells Targeting CD5/CD7 in patients with patients with relapsed or refractory T-ALL/LBL/ETP-ALL. The primary goal is safety assessment including cytokine storm response and any other adverse effects. In addition, disease status after treatment will also be evaluated.
100 项与 CD5/CD7 CAR-T(Essen Biotech) 相关的临床结果
100 项与 CD5/CD7 CAR-T(Essen Biotech) 相关的转化医学
100 项与 CD5/CD7 CAR-T(Essen Biotech) 相关的专利(医药)
100 项与 CD5/CD7 CAR-T(Essen Biotech) 相关的药物交易